Last reviewed · How we verify

NCT06677762

Irreversible Electroporation Ablation Combined With Anti-PD(L)1 Therapy for Locally Advanced Pancreatic Cancer

Not yet recruiting Last updated 7 November 2024
What this trial tests

trial testing Irreversible electroporation in Pancreatic Cancer in 55 participants. Not yet recruiting.

Timeline
10 November 2024
Primary endpoint
30 June 2025
30 June 2025

Quick facts

Lead sponsorRuijin Hospital
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment55
Start date10 November 2024
Primary completion30 June 2025
Estimated completion30 June 2025

Drugs / interventions tested

Conditions studied

Sponsor

Ruijin Hospital

Who can join

18 and older, any sex, with Pancreatic Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Pancreatic cancer is a highly lethal malignant tumor of the digestive tract, especially local advanced pancreatic cancer (LAPC), which often loses the opportunity for surgical resection at the time of diagnosis. LAPC patients are often accompanied by tumor invasion of key anatomical structures such as major blood vessels, and traditional treatment methods such as radiotherapy and chemotherapy can slow down the progression of the disease, but the effect is limited, and the overall survival rate is still very low. There is a lack of effective treatment options for LAPC, especially in local control and prolonging survival, which exists a major limitation. The surgical resection rate is low in LAPC, and the postoperative recurrence rate is high, and traditional radiotherapy and chemotherapy are difficult to completely eliminate the tumor. Immunotherapy has achieved breakthroughs in other tumors such as melanoma and non-small cell lung cancer, but the effect is limited in pancreatic cancer due to the immunosuppressive state of the tumor microenvironment (TME), which limits the efficacy of immunotherapy. In addition, the high invasiveness and rapid progression of pancreatic cancer further aggravates the treatment challenge. Recent studies have shown that local ablation techniques such as irreversible electroporation (IRE) ablation not only can effectively ablate local tumors, but also may destroy the structural integrity of tumor cells, release tumor-associated antigens, and enhance the anti-tumor effect of the immune system. Therefore, IRE ablation may provide local control of pancreatic cancer for patients. At the same time, the combination of immune checkpoint inhibitors such as anti-PD(L)1 inhibitors may enhance the immune response in the tumor microenvironment and further improve the therapeutic effect. This combined treatment regimen is expected to overcome the limitations of single therapy and provide a new treatment strategy for local advanced pancreatic cancer.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Pulsed electric fields: a sharp sword in the battle against cancers.
    Zhang L, Dong S, Teng F, Wang Y, et al · · 2025 · PMID 41357174 · DOI 10.3389/fimmu.2025.1682539

Verify or expand the search:

Other trials of Irreversible electroporation

Trials testing the same drug.

Other recruiting trials for Pancreatic Cancer

Currently open trials in the same condition.

Other Ruijin Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06677762.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing